Novalis Biotechnology Incubation
Novalis Biotech is an early-stage venture capital fund focused on enabling technologies in life sciences. The firm invests in capital-light platform technologies from (pre-)seed to Series A, concentrating on bioinformatics, genomics, diagnostics, digital health, research and manufacturing tools. Novalis provides funding and active operational support including strategic guidance, network access and governance representation to accelerate commercialization and company development.
Industries
Nr. of Employees
small (1-50)
Novalis Biotechnology Incubation
Novalis Biotech Fund, Ottergemsesteenweg – Zuid 808, 9000 Ghent, Belgium (Google Maps: https://goo.gl/maps/1knq1dNAy3d5eJAr9)
Portfolio
ISO 13485:2016 and ISO 27001:2013-certified; CE-marked and FDA-cleared electrophysiology applications; Novalis listed as investor in 2025 news item.
#MedTech (electrophysiology, CNS applications)
AI analysis of standard medical images to detect early joint damage; Novalis participated in seed investment.
#Medical imaging AI (rheumatology)
Developing 'Artificial Voice' using non-invasive radar sensing and neural networks; Novalis participated in Series A.
#Medical device (AI-based voice rehabilitation)
Develops superRCA ultrasensitive multiplex assay read out by flow cytometry; Novalis invested and participated in funding rounds (2023, 2024).
#Genomics / molecular diagnostics
Digital health solution for diagnosis and management of cough-related conditions; Novalis participated in seed extension.
#Digital health (cough assessment and monitoring)
Patented microcarrier technology enabling 3D cell cultivation; partnership with Etablissement Français du Sang (EFS) validated microcarriers and led to early commercial orders.
#Biomanufacturing / cell culture microcarriers
ISO 13485:2016 and ISO 27001:2013-certified; CE-marked and FDA-cleared electrophysiology applications; Novalis listed as investor in 2025 news item.
#MedTech (electrophysiology, CNS applications)
AI analysis of standard medical images to detect early joint damage; Novalis participated in seed investment.
#Medical imaging AI (rheumatology)
Developing 'Artificial Voice' using non-invasive radar sensing and neural networks; Novalis participated in Series A.
#Medical device (AI-based voice rehabilitation)
Develops superRCA ultrasensitive multiplex assay read out by flow cytometry; Novalis invested and participated in funding rounds (2023, 2024).
#Genomics / molecular diagnostics
Digital health solution for diagnosis and management of cough-related conditions; Novalis participated in seed extension.
#Digital health (cough assessment and monitoring)
Patented microcarrier technology enabling 3D cell cultivation; partnership with Etablissement Français du Sang (EFS) validated microcarriers and led to early commercial orders.
#Biomanufacturing / cell culture microcarriers